211 related articles for article (PubMed ID: 27058226)
21. Identification and characterization of HIV-1 epitopes presented by HLA-A*2603: comparison between HIV-1 epitopes presented by A*2601 and A*2603.
Kawashima Y; Satoh M; Oka S; Takiguchi M
Hum Immunol; 2005 Nov; 66(11):1155-66. PubMed ID: 16571416
[TBL] [Abstract][Full Text] [Related]
22. Cross-reactive memory T cells for Epstein-Barr virus augment the alloresponse to common human leukocyte antigens: degenerate recognition of major histocompatibility complex-bound peptide by T cells and its role in alloreactivity.
Burrows SR; Silins SL; Khanna R; Burrows JM; Rischmueller M; McCluskey J; Moss DJ
Eur J Immunol; 1997 Jul; 27(7):1726-36. PubMed ID: 9247584
[TBL] [Abstract][Full Text] [Related]
23. Improved Transgenic Mouse Model for Studying HLA Class I Antigen Presentation.
Huang M; Zhang W; Guo J; Wei X; Phiwpan K; Zhang J; Zhou X
Sci Rep; 2016 Sep; 6():33612. PubMed ID: 27634283
[TBL] [Abstract][Full Text] [Related]
24. Nonclassical HLA-G molecules are classical peptide presenters.
Diehl M; Münz C; Keilholz W; Stevanović S; Holmes N; Loke YW; Rammensee HG
Curr Biol; 1996 Mar; 6(3):305-14. PubMed ID: 8805247
[TBL] [Abstract][Full Text] [Related]
25. The effect of proteasome inhibition on the generation of the human leukocyte antigen (HLA) peptidome.
Milner E; Gutter-Kapon L; Bassani-Strenberg M; Barnea E; Beer I; Admon A
Mol Cell Proteomics; 2013 Jul; 12(7):1853-64. PubMed ID: 23538226
[TBL] [Abstract][Full Text] [Related]
26. Unsupervised HLA Peptidome Deconvolution Improves Ligand Prediction Accuracy and Predicts Cooperative Effects in Peptide-HLA Interactions.
Bassani-Sternberg M; Gfeller D
J Immunol; 2016 Sep; 197(6):2492-9. PubMed ID: 27511729
[TBL] [Abstract][Full Text] [Related]
27. Generating data for databases--the peptide repertoire of HLA molecules.
Stevanović S; Lemmel C; Häntschel M; Eberle U
Novartis Found Symp; 2003; 254():143-55; discussion 155-64, 216-22, 250-2. PubMed ID: 14712936
[TBL] [Abstract][Full Text] [Related]
28. Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry.
Freudenmann LK; Marcu A; Stevanović S
Immunology; 2018 Jul; 154(3):331-345. PubMed ID: 29658117
[TBL] [Abstract][Full Text] [Related]
29. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
[TBL] [Abstract][Full Text] [Related]
30. Quantifying epitope presentation using mass spectrometry.
Croft NP; Purcell AW; Tscharke DC
Mol Immunol; 2015 Dec; 68(2 Pt A):77-80. PubMed ID: 26118903
[TBL] [Abstract][Full Text] [Related]
31. Mycobacterium tuberculosis peptides presented by HLA-E molecules are targets for human CD8 T-cells with cytotoxic as well as regulatory activity.
Joosten SA; van Meijgaarden KE; van Weeren PC; Kazi F; Geluk A; Savage ND; Drijfhout JW; Flower DR; Hanekom WA; Klein MR; Ottenhoff TH
PLoS Pathog; 2010 Feb; 6(2):e1000782. PubMed ID: 20195504
[TBL] [Abstract][Full Text] [Related]
32. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
[TBL] [Abstract][Full Text] [Related]
33. A comprehensive analysis of constitutive naturally processed and presented HLA-C*04:01 (Cw4)-specific peptides.
Schittenhelm RB; Dudek NL; Croft NP; Ramarathinam SH; Purcell AW
Tissue Antigens; 2014 Mar; 83(3):174-9. PubMed ID: 24397554
[TBL] [Abstract][Full Text] [Related]
34. Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma.
Alatrash G; Perakis AA; Kerros C; Peters HL; Sukhumalchandra P; Zhang M; Jakher H; Zope M; Patenia R; Sergeeva A; Yi S; Young KH; Philips AV; Cernosek AM; Garber HR; Qiao N; Weng J; St John LS; Lu S; Clise-Dwyer K; Mittendorf EA; Ma Q; Molldrem JJ
Clin Cancer Res; 2018 Jul; 24(14):3386-3396. PubMed ID: 29661776
[No Abstract] [Full Text] [Related]
35. The Length Distribution and Multiple Specificity of Naturally Presented HLA-I Ligands.
Gfeller D; Guillaume P; Michaux J; Pak HS; Daniel RT; Racle J; Coukos G; Bassani-Sternberg M
J Immunol; 2018 Dec; 201(12):3705-3716. PubMed ID: 30429286
[TBL] [Abstract][Full Text] [Related]
36. High immunogenicity of the human leukocyte antigen peptidomes of melanoma tumor cells.
Jarmalavicius S; Welte Y; Walden P
J Biol Chem; 2012 Sep; 287(40):33401-11. PubMed ID: 22869377
[TBL] [Abstract][Full Text] [Related]
37. Class I HLA folding and antigen presentation in beta 2-microglobulin-defective Daudi cells.
Martayan A; Sibilio L; Tremante E; Lo Monaco E; Mulder A; Fruci D; Cova A; Rivoltini L; Giacomini P
J Immunol; 2009 Mar; 182(6):3609-17. PubMed ID: 19265139
[TBL] [Abstract][Full Text] [Related]
38. Toward a definition of self: proteomic evaluation of the class I peptide repertoire.
Hickman HD; Luis AD; Buchli R; Few SR; Sathiamurthy M; VanGundy RS; Giberson CF; Hildebrand WH
J Immunol; 2004 Mar; 172(5):2944-52. PubMed ID: 14978097
[TBL] [Abstract][Full Text] [Related]
39. Role of APC in the selection of immunodominant T cell epitopes.
Ma C; Whiteley PE; Cameron PM; Freed DC; Pressey A; Chen SL; Garni-Wagner B; Fang C; Zaller DM; Wicker LS; Blum JS
J Immunol; 1999 Dec; 163(12):6413-23. PubMed ID: 10586031
[TBL] [Abstract][Full Text] [Related]
40. Proteasome inhibitor lactacystin augments natural killer cell cytotoxicity of myeloma via downregulation of HLA class I.
Wu X; Shao Y; Tao Y; Ai G; Wei R; Meng X; Hou J; Han Y; Zhan F; Zheng J; Shi J
Biochem Biophys Res Commun; 2011 Nov; 415(1):187-92. PubMed ID: 22033416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
